The Many Varieties Of 'Emerging' - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Many Varieties Of 'Emerging'


Pharmaceutical Technology Europe
Volume 23, Issue 8


C.O.T/a.collectionRF/Getty Images
Much has been written about the importance of emerging markets for driving future growth, but while most companies recognise their significance, they struggle to jump the first hurdle in addressing these opportunities: defining the right product. Many mistakes arise from the single misconception that emerging markets are all broadly the same and that you can tackle them with a single common strategy.

But you can't. To avoid this mistake as you develop your product strategy, keep in mind some common pitfalls:

  • Don't assume uniformity across or within markets. Differences may include: socio-economic, appropriate business model, geographic, cultural, supply chain, infrastructure, regulatory/intellectual property and physical differences.
  • Carefully define the scope of your customer research. When researching unmet needs, you will need to go beyond just focusing on stakeholders and settings within your niche. Emerging markets have entirely different ecosystems that extend beyond your limited setting. You need to understand the relationships along the entire clinical pathway and not just the step(s) during which your product is used. If you don't, you risk completely missing important commercial, user and technical insights that can make-or-break your product.
  • If the necessary experience isn't in your group, consider looking to other divisions within your organisation, or you may need to partner externally.
  • Make sure your plan includes a well-researched strategy for local sourcing and manufacturing. Consider this upfront during your research—don't wait until the end.
  • More than ever, when building product concepts, challenge your old assumptions and explore frugal innovation as a route to real breakthroughs.
  • Last but not least, cost is important, but it's not everything. Your aim is still to get the right product at the right cost and with the right level of availability.


Do you believe that a single corporate strategy is sufficient for the fragmented nature of the emerging markets? Source: www.pharmtech.com poll, conducted June-July 2011.
These are just a few of the considerations that companies should take into account when entering these markets. Regardless of your approach, it's worth getting it "right" because it could be one of the keys to sustainable growth.

Cole Shelton is an innovation and technology management consultant at Sagentia Ltd.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here